Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

Completed · Phase 1 · Has a placebo group

Conditions studied: NAFLD

In brief

BRB-018-001 is a multicenter, adaptive design, randomized, parallel group study to evaluate the safety, tolerability, and PK of repeat IV doses of RYI-018 in subjects with NAFLD.

Key facts

Study ID

NCT03261739

Run by

Bird Rock Bio, Inc.

People needed

84

Starts

2017-08-28

Expected to finish

2018-08-24

Last updated by the study team

2019-03-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• BRB Site — Chula Vista, California, United States
• BRB Site — Miami, Florida, United States
• BRB Site — Orlando, Florida, United States
• BRB Site — San Antonio, Texas, United States
• BRB Site — Nedlands, Western Australia, Australia
• BRB Site — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.